
|Articles|January 15, 2004
Prostaglandin analogs help patients stick with regimen
Author(s)Cheryl Guttman
Baltimore-Patients prescribed latanoprost (Xalatan, Pfizer Ophthalmics) continue therapy significantly longer than their counterparts using other prostaglandin-type drugs, according to the results of a population-based, retrospective cohort study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sandoz Canada launches aflibercept biosimilar, Enzeevum
2
AMD and low vision awareness month: Using the MTII to evaluate progression of GA
3
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
4
The Residency Report: PreserFlo microshunt vs trabeculectomy—five-year trial insights
5




























